The Different Effect of VEGF Polymorphisms on the Prognosis of Non-Small Cell Lung Cancer According to Tumor Histology

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2016 Oct 7

PMID 27709850

Citations 5

Authors

Soyeon Lee

Hyo Gyoung Kang

Jin Eun Choi

Jang Hyuck Lee

Hyo Jung Kang

Sun Ah Baek

Eungbae Lee

Yangki Seok

Won Kee Lee

Shin Yup Lee

Seung Soo Yoo

Jaehee Lee

Seung Ick Cha

Chang Ho Kim

Sukki Cho

Jae Yong Park

Affiliations

Soon will be listed here.

Abstract

Vascular endothelial growth factor (VEGF) contributes to tumor angiogenesis. The role of VEGF single nucleotide polymorphisms (SNPs) in lung cancer susceptibility and its prognosis remains inconclusive and controversial. This study was performed to investigate whether VEGF polymorphisms affect survival outcomes of patients with early stage non-small cell lung cancer (NSCLC) after surgery. Three potentially functional VEGF SNPs (rs833061T>C, rs2010963G>C, and rs3025039C>T) were genotyped. A total of 782 NSCLC patients who were treated with surgical resection were enrolled. The association of the SNPs with overall survival (OS) and disease free survival (DFS) was analyzed. In overall population, none of the three polymorphisms were significantly associated with OS or DFS. However, when the patients were stratified by tumor histology, squamous cell carcinoma (SCC) and adenocarcinoma (AC) had significantly different OS (Adjusted hazard ratio [aHR] = 0.76, 95% CI = 0.56-1.03 in SCC; aHR = 1.33, 95% CI = 0.98-1.82 in AC; P for heterogeneity = 0.01) and DFS (aHR = 0.75, 95% CI = 0.58-0.97 in SCC; aHR = 1.26, 95% CI = 1.00-1.60 in AC; P for heterogeneity = 0.004) according to the rs833061T>C genotypes. Our results suggest that the prognostic role of VEGF rs833061T>C may differ depending on tumor histology.

Citing Articles

JAK2 Loss Arising From Tumor-Spread-Through-Air-Spaces (STAS) Promotes Tumor Progression by Suppressing CD8+ T Cells in Lung Adenocarcinoma: A Machine Learning Approach.

Choi S, Kim H, Min K, Noh Y, Lee J, Moon J J Korean Med Sci. 2024; 39(2):e16.

PMID: 38225784 PMC: 10789524. DOI: 10.3346/jkms.2024.39.e16.

T4 Lung Carcinoma with Infiltration of the Thoracic Aorta: Indication and Surgical Procedure.

Irqsusi M, Ghazy T, Vogt S, Mirow N, Kirschbaum A Cancers (Basel). 2023; 15(19).

PMID: 37835540 PMC: 10572069. DOI: 10.3390/cancers15194847.

LncRNA-UCA1 regulates lung adenocarcinoma progression through competitive binding to miR-383.

Tang L, Wang S, Wang Y, Li K, Li Q Cell Cycle. 2022; 22(2):213-228.

PMID: 35980157 PMC: 9817116. DOI: 10.1080/15384101.2022.2111929.

Hypoxia in Lung Cancer Management: A Translational Approach.

Ancel J, Perotin J, Dewolf M, Launois C, Mulette P, Nawrocki-Raby B Cancers (Basel). 2021; 13(14).

PMID: 34298636 PMC: 8307602. DOI: 10.3390/cancers13143421.

Exposure to selected limonene oxidation products: 4-OPA, IPOH, 4-AMCH induces oxidative stress and inflammation in human lung epithelial cell lines.

Lipsa D, Barrero-Moreno J, Coelhan M Chemosphere. 2017; 191:937-945.

PMID: 29145138 PMC: 5701770. DOI: 10.1016/j.chemosphere.2017.10.065.

References

Han H, Silverman J, Santucci T, Macherey R, dAmato T, Tung M . Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 2001; 8(1):72-9. DOI: 10.1007/s10434-001-0072-y. View

Tu J, Wang S, Zhao J, Zhu J, Sheng L, Sheng Y . rs833061 and rs699947 on promoter gene of vascular endothelial growth factor (VEGF) and associated lung cancer susceptibility and survival: a meta-analysis. Med Sci Monit. 2014; 20:2520-6. PMC: 4263404. DOI: 10.12659/MSM.891394. View

Chen M, Cai E, Huang J, Yu P, Li K . Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012; 21(7):1126-34. DOI: 10.1158/1055-9965.EPI-12-0020. View

Guan X, Yin M, Wei Q, Zhao H, Liu Z, Wang L . Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer. 2010; 10:431. PMC: 2939547. DOI: 10.1186/1471-2407-10-431. View

Vincenti V, CASSANO C, Rocchi M, Persico G . Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996; 93(8):1493-5. DOI: 10.1161/01.cir.93.8.1493. View

Vaupel P . The role of hypoxia-induced factors in tumor progression. Oncologist. 2004; 9 Suppl 5:10-7. DOI: 10.1634/theoncologist.9-90005-10. View

Herbst R, Heymach J, Lippman S . Lung cancer. N Engl J Med. 2008; 359(13):1367-80. PMC: 10662965. DOI: 10.1056/NEJMra0802714. View

Sekido Y, Fong K, Minna J . Molecular genetics of lung cancer. Annu Rev Med. 2002; 54:73-87. DOI: 10.1146/annurev.med.54.101601.152202. View

Eilertsen M, Pettersen I, Andersen S, Martinez I, Donnem T, Busund L . In NSCLC, VEGF-A response to hypoxia may differ between squamous cell and adenocarcinoma histology. Anticancer Res. 2012; 32(11):4729-36. View

10.

Yuan A, Yang P, Yu C, Lee Y, Yao Y, Chen C . Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer. Am J Respir Crit Care Med. 1995; 152(6 Pt 1):2157-62. DOI: 10.1164/ajrccm.152.6.8520790. View

11.

Bradbury P, Zhai R, Ma C, Xu W, Hopkins J, Kulke M . Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res. 2009; 15(14):4680-5. PMC: 2742698. DOI: 10.1158/1078-0432.CCR-09-0192. View

12.

Hefler L, Mustea A, Konsgen D, Concin N, Tanner B, Strick R . Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res. 2007; 13(3):898-901. DOI: 10.1158/1078-0432.CCR-06-1008. View

13.

Hockel M, Vaupel P . Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001; 93(4):266-76. DOI: 10.1093/jnci/93.4.266. View

14.

Masago K, Fujita S, Kim Y, Hatachi Y, Fukuhara A, Nagai H . Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci. 2009; 100(10):1917-22. PMC: 11159069. DOI: 10.1111/j.1349-7006.2009.01253.x. View

15.

Schettino C, Bareschino M, Rossi A, Maione P, Castaldo V, Mazzeo N . The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer. Ther Adv Med Oncol. 2011; 1(1):5-13. PMC: 3125989. DOI: 10.1177/1758834009338635. View

16.

Yuan A, Yu C, Chen W, Lin F, Kuo S, Luh K . Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer. 2000; 89(6):475-83. DOI: 10.1002/1097-0215(20001120)89:6<475::aid-ijc2>3.0.co;2-t. View

17.

OByrne K, Koukourakis M, Giatromanolaki A, Cox G, Turley H, Steward W . Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer. 2000; 82(8):1427-32. PMC: 2363365. DOI: 10.1054/bjoc.1999.1129. View

18.

Weis S, Cheresh D . Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011; 17(11):1359-70. DOI: 10.1038/nm.2537. View

19.

Hoeben A, Landuyt B, Highley M, Wildiers H, van Oosterom A, De Bruijn E . Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004; 56(4):549-80. DOI: 10.1124/pr.56.4.3. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View